The NFX1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered from the human Raji B lymphocyte cell line to disrupt the NFX1 gene. This product provides a heterogeneous loss-of-function model in which targeted gene disruption eliminates functional NFX1 protein expression without clonal selection, making it suitable for studying bulk cellular responses and pathway-level effects in a malignant B-cell context.
Derived from an EBV-positive Burkitt lymphoma, Raji cells are widely adopted for investigating humoral immunity, antigen presentation, and lymphomagenesis. Their malignant B-lymphoblastoid origin and persistent proliferation make them an ideal host for examining oncogenic signaling and immune evasion strategies. The cell line??s established use in functional assays further enhances the model??s translational relevance.
NFX1 functions as a transcriptional repressor that critically regulates major histocompatibility complex (MHC) class II expression and telomerase activity. Mechanistically, NFX1 binds to X-box motifs within MHC class II promoters and recruits the P-TEFb complex, comprising CDK9 and CCNT1, to inhibit transcriptional elongation of HLA-DR, HLA-DQ, and HLA-DP genes. This repressive activity is modulated by upstream signals from Notch receptors, interferon-gamma (IFN-??), and tumor necrosis factor (TNF). Additionally, NFX1 influences telomerase reverse transcriptase (TERT) expression and interacts with telomerase complex components, linking it to proliferative control.
In the Raji host cell background, NFX1 disruption provides a unique tool to dissect how loss of this repressor impacts MHC class II surface levels and telomerase-dependent proliferation. Because NFX1 typically suppresses antigen presentation and sustains telomere maintenance, its knockout may restore MHC class II expression and attenuate telomerase activity, offering insights into immune evasion in Burkitt lymphoma and other B-cell malignancies.
Key research applications include studying MHC class II gene regulation, investigating telomerase function in B-cell cancers, and exploring Notch and NF-??B signaling dynamics. The polyclonal population is well-suited for assays such as flow cytometry for MHC class II surface expression, telomerase activity (TRAP) assays, co-immunoprecipitation of P-TEFb and RFX complex components, and proliferation analyses. For further details or to discuss custom applications, please contact Ascent Research.
